Verona Pharma: Rises on FDA go-ahead for late-stage lung disease drug study

Verona Pharma

14/05/2020 13:36

** U.S.-listed shares of UK-based drug developer  VRNA.O 
rise 22.3% to $4.6 premarket 
    ** Company says it has received written approval from the
U.S. FDA to begin late-stage study of its lung disease drug,
nebulized ensifentrine  urn:newsml:reuters.com:*:nGNE6NgDhV
    ** Trial is expected to start later in 2020
    ** Company had reported positive results from a mid-stage
trial in January
    ** Stock has fallen 34.8% YTD


 (Reporting by Dania Nadeem in Bengaluru)
 ((mailto:dania.nadeem@thomsonreuters.com))